Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: COPD, QVA149
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1042
Healthy volunteers: no

Brief summary:
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.

Detailed description:
NOTE: Detailed Description: data not entered

Arms:
arm 1: 27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI) arm 2: 27.5 ug b.i.d. arm 3: 12.5 ug b.i.d. arm 4: b.i.d

Interventions: intervention 1: QVA149 intervention 2: QAB149 intervention 3: NVA237 intervention 4: Placebo
Intervention descriptions: intervention 1: QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI intervention 2: QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI. intervention 3: NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI. intervention 4: Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Protocol document: